← Trials/Trial dossier/NCT00362024

TerminatedPhase 2

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease

Lead sponsor

Merck Sharp & Dohme LLC

Asset

MK0952

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•CDR global 1•MMSE 18-26•Study partner/caregiver required•AD symptomatic therapy: stable ≥6 months

Primary endpoint

Identifiers

Registered as

Org study ID0952-004

Secondary2006_026

NCT IDNCT00362024

Timeline

Milestones

Study first posted2006-08-09estimated

Study start2006-11 (month precision)

Primary completion2007-11actual (month precision)

Study completion2007-11actual (month precision)

Last update posted2016-05-16estimated

Assets

Drug assets

MK0952

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or females

•Age >/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score </= 4, Global CDR score of 1 or 2

•Who have a reliable informant/caregiver to accompany patient to all clinic visits

•If using a symptomatic AD treatments, patients must be on stable dose for >/= 6 months

Exclusion criteria

•Patients must not be living in nursing home or skilled nursing facility

•Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis

•Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF

•Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder

•Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)

•Various concomitant therapy restrictions

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.